Home›Stock Screener›Transgene Biotek›Intrinsic Value

Transgene Biotek Intrinsic Value

Transgene Biotek intrinsic value. Transgene Biotek (TRABI) median intrinsic value is ₹2.11 from 1 valuation models (range ₹2–₹2), vs current price ₹2.49 — -15.3% downside (Trading Above Median Value), margin of safety -18.0%. Browse Transgene Biotek annual reports for revenue, profit, balance sheet and cash flow data.

Market Price (CMP)
₹2.49
Primary Intrinsic Value
₹2.11
Market Cap
₹18.9 Cr
-15.3% Downside
Median Value
₹2.11
Value Range
₹2 - ₹2
Assessment
Trading Above Median Value
Safety Margin
-18.0%

TRABI Valuation Methods Summary — DCF, Graham Number & P/E

Transgene Biotek intrinsic value across 1 models vs current price ₹2.49 — upside/downside and value range per method. For current market price and key ratios, visit TRABI share price screener.

Method Type Intrinsic Value Range Upside/Downside Details
Book Value Method asset ₹2.11 ₹1.90 - ₹2.32 -15.3% Book Value/Share: ₹1.05, P/B: 2.0x
Method Types: Earnings Asset DCF Growth Dividend Conservative

TRABI Intrinsic Value vs Market Price — All Valuation Models

Transgene Biotek fair value range ₹2–₹2 vs current market price ₹2.49 across 1 valuation models. Analyse TRABI shareholder distribution to track promoter, FII and institutional holdings.

TRABI Intrinsic Value Analysis — Undervalued or Overvalued?

Transgene Biotek median intrinsic value ₹2.11, current price ₹2.49 — Trading Above Median Value by 15.3%, margin of safety -18.0%.

What is the intrinsic value of TRABI?

Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Transgene Biotek (TRABI) is ₹2.11 (median value). With the current market price of ₹2.49, this represents a -15.3% variance from our estimated fair value.

The valuation range spans from ₹2.11 to ₹2.11, indicating ₹2.11 - ₹2.11.

Is TRABI undervalued or overvalued?

Based on our multi-method analysis, Transgene Biotek (TRABI) appears to be trading above median value by approximately 15.3%.

TRABI Financial Health — Key Ratios vs Industry Benchmarks

Transgene Biotek financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity -50.0% Industry Standard: 15%+ Below 10% Measures shareholder return efficiency
Operating Margin -560.0% Industry Standard: 20%+ Below 10% Indicates operational efficiency level

TRABI Cash Flow Quality — Operating & Free Cash Flow

Transgene Biotek operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2025 ₹1 Cr ₹0 Cr Positive Operating Cash Flow 6/10
March 2024 ₹0 Cr ₹0 Cr Negative Cash Flow 3/10
March 2023 ₹0 Cr ₹0 Cr Negative Cash Flow 3/10
March 2022 ₹0 Cr ₹0 Cr Negative Cash Flow 3/10
March 2021 ₹0 Cr ₹0 Cr Negative Cash Flow 3/10